Abstract The Japanese Society of Gastroenterology revised the evidence-based clinical
practice guidelines for liver cirrhosis in 2015. Eighty-three clinical questions were selected …

Liver fibrosis represents a significant health problem worldwide of which no acceptable
therapy exists. The most characteristic feature of liver fibrosis is excess deposition of type I …

Background & Aims Cancer-associated fibroblasts (CAFs) play a key role in the cancer
process, but the research progress is hampered by the paucity of preclinical models that are …

Patients should be considered for liver transplantation if they have evidence of fulminant
hepatic failure, a life-threatening systemic complication of liver disease, or a liver-based …

Hepatitis C virus (HCV) infection is a leading cause of liver transplantation and there is an
urgent need to develop therapies to reduce rates of HCV infection of transplanted livers …

BACKGROUND/AIMS: HCV infection recurs almost in all HCV-positive patients receiving
liver transplantation and carries a poor prognosis. Aim of this study was to analyze efficacy …

Liver transplantation is currently the only definitive modality for the treatment of end‐stage
liver disease due to chronic hepatitis C. However, recurrent hepatitis C after liver …

BACKGROUNDS/AIMS: Recurrent HCV-cirrhosis occurs in a substantial proportion of
transplant recipients, with higher rates reported in patients who had recently received a …

A controversy exists over whether the outcome of a hepatitis C virus (HCV)‐infection‐related
liver transplant differs based on the calcineurin inhibitor (CNI) used. We have performed a …

Hepatitis C virus (HCV) cirrhosis is the most common indication for liver transplantation in
developed countries. Re-infection of liver allografts is virtually universal and occurs at …